BiotechTube

idebenone + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Friedreich's Ataxia

Conditions

Friedreich's Ataxia

Trial Timeline

Apr 1, 2006 → Jan 1, 2010

NCT ID
NCT00905268

About idebenone + Placebo

idebenone + Placebo is a phase 3 stage product being developed by Santhera Pharmaceuticals for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT00905268. Target conditions include Friedreich's Ataxia.

What happened to similar drugs?

0 of 6 similar drugs in Friedreich's Ataxia were approved

Approved (0) Terminated (0) Active (6)
🔄Interferon γ-1bAmgenPhase 3
🔄interferon γ-1bAmgenPhase 3
🔄Interferon γ-1b + PlaceboAmgenPhase 3
🔄Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
🔄IdebenoneSanthera PharmaceuticalsPhase 3
🔄Idebenone + PlaceboSanthera PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT01495715Phase 3Withdrawn
NCT01303406Phase 3Completed
NCT00747487Phase 2Completed
NCT00905268Phase 3Completed
NCT00654784Phase 2Completed

Competing Products

11 competing products in Friedreich's Ataxia

See all competitors
ProductCompanyStageHype Score
Interferon γ-1bAmgenPhase 3
40
interferon γ-1bAmgenPhase 3
40
Interferon γ-1b + PlaceboAmgenPhase 3
40
varenicline + placeboPfizerPhase 2/3
30
Lu AA24493 + PlaceboLundbeckPhase 2
32
OmeveloxoloneBiogenPre-clinical
30
Placebo + EPI-743 400 mg + EPI-743 200 mgPTC TherapeuticsPhase 2
32
SGT-212Solid BiosciencesPhase 1
30
Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
30
IdebenoneSanthera PharmaceuticalsPhase 3
30
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
30